Endoxifen

DRUG2 trials

Sponsors

Intas Pharmaceuticals Limited, Jina Pharmaceuticals Inc.

Conditions

Bipolar I Disorder

Phase 3

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

CompletedNCT04315792

Jina Pharmaceuticals Inc.Bipolar I Disorder

Start: 2020-08-03End: 2021-08-25Updated: 2024-09-23

A Double-Blind, Oral, Placebo-Controlled, Multiple-Dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

CompletedCTIS2024-511829-57-00

Intas Pharmaceuticals LimitedBipolar I Disorder

End: 2025-04-02Target: 27Updated: 2025-02-07